New Draxxin® KP, a Combination Treatment for Bovine Respiratory Disease (BRD) From Zoetis

Draxxin® KP (tulathromycin and ketoprofen Injection) Injectable Solution now 
available to both treat BRD and control fever in one treatment

PARSIPPANY, N.J., Aug. 9, 2021 — Zoetis today announced a new combination product to treat bovine respiratory disease (BRD) and control related fever (pyrexia): Draxxin® KP (tulathromycin and ketoprofen injection) Injectable Solution. It’s a new single-treatment option for beef and dairy producers. 

Draxxin KP includes the well-known effectiveness of Draxxin® (tulathromycin injection) Injectable Solution and adds ketoprofen, a fast-acting nonsteroidal anti-inflammatory drug (NSAID), in a single treatment approved for use in beef steers, beef heifers, beef calves two months of age and older, beef bulls, dairy bulls and dairy replacement heifers.

“With BRD, there can be an underlying fever, which can progress quickly and lead to appetite loss,” said Shawn Blood, DVM, managing technical services veterinarian at Zoetis. “Using an NSAID together with an antibiotic can aid treatment response and reduce the fever that typically comes with BRD compared with using an antibiotic treatment alone. Draxxin KP provides the option and convenience to have two powerful, effective ingredients working together.”  

One Shot, Two Effective Ingredients 
In one subcutaneous injection, Draxxin KP starts working fast — both products have a rapid onset1 — against fever and four major bacterial pathogens associated with BRD: 

Control fever: Because Draxxin KP includes an NSAID, it controls the fever that typically comes with BRD. The fast-acting anti-inflammatory, ketoprofen, has been demonstrated to reduce temperatures in as little as one hour.
Treat four major BRD pathogens: Draxxin KP provides the same long-acting antibacterial activity that Draxxin has against four major bacterial pathogens (Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis) associated with BRD for up to 14 days.1 

Fast Facts About Draxxin® KP (tulathromycin and ketoprofen injection) Injectable Solution 
• One shot, administered subcutaneously 
• Treats BRD and controls fever in beef steers, beef heifers, beef calves two months of age and older, beef bulls, dairy bulls and dairy replacement heifers 
• Low-volume dose of 2.5 mg tulathromycin and 3.0 mg ketoprofen/kg or 1.1 mL per 100 pounds body weight 
• Short meat withdrawal of 18 days 
• Draxxin KP has the same dose size and viscosity as Draxxin, so you should expect the same year-round syringeability as Draxxin. 
• Maintains therapeutic level of tulathromycin for approximately 14 days1

Demonstrated Fast BRD Recovery in Multisite Studies 
Draxxin KP was demonstrated in two multisite studies in the United States and EU:

A fast treatment for BRD-related fever: Studies found Draxxin KP demonstrated a significant reduction of  BRD-associated fever from one hour up to 24 hours after treatment compared with Draxxin alone.2,3  
An effective BRD treatment: Studies showed Draxxin KP had a significantly greater BRD treatment success rate compared with calves treated with saline and similar treatment success rates with calves receiving Draxxin alone.1,2 

“When cattle get sick, fast and successful treatment is crucial,” Dr. Blood said. “Draxxin KP is demonstrated to treat BRD and control fever effectively, which can help cattle feel better and improve overall well-being.4,5* Additionally, first-treatment success can help reduce the need for subsequent and overall antibiotic treatments,6 which helps ensure important antibiotics remain effective into the future.” 

The addition of Draxxin® KP enhances the leading portfolio of BRD treatment options from Zoetis.7 To learn more about Draxxin KP, contact your veterinarian or visit www.draxxinkp.com. 

About Zoetis 
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide — from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, Zoetis generated revenue of $6.7 billion with ~11,300 employees. For more, visit www.zoetis.com.

IMPORTANT SAFETY INFORMATION FOR DRAXXIN KP: Draxxin KP has a pre-slaughter withdrawal time of 18 days in cattle. Not for use in female dairy cattle 1 year of age or older, including dry dairy cows. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in animals previously found to be hypersensitive to tulathromycin and ketoprofen. See full Prescribing Information.

IMPORTANT SAFETY INFORMATION FOR DRAXXIN: Draxxin has a pre-slaughter withdrawal time of 18 days in cattle. Do not use in female dairy cattle 20 months of age or older. Do not use in animals known to be hypersensitive to the product. See full Prescribing Information.

IMPORTANT SAFETY INFORMATION FOR KETOFEN: Ketofen has a pre-slaughter withdrawal time of within 48 hours following last treatment. Not for use in female dairy cattle 1 year of age or older, including dry dairy cows. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in animals showing hypersensitivity to ketoprofen. The effects of Ketofen on bovine reproductive performance, pregnancy, lactation, or on animals of reproductive age intended for breeding has not been studied. See full Prescribing Information.

*Draxxin KP animals showed a numerically improved attitude and respiratory scores compared with saline-treated and Draxxin-treated animals.6

1 Data on file, Study Report No. A431N-US-16-418, Zoetis Inc. 
2 Data on file, Study Report No. A136R-US-16-508, Zoetis Inc.  
3 Data on file, Study Report No. A131C-US-17-531, Zoetis Inc. (U.S.) 
4 Poulsen Nautrup B, Van Vlaenderen I, Decker M, Cleale RM. Antimicrobial drug use for control and treatment of bovine respiratory disease in U.S. feedlot cattle: A meta-analysis. Bov Pract. 2017;51(1);1-13. 
5 Freedom of Information Summary. NADA TBD — Draxxin® KP (tulathromycin and ketoprofen Injection). Food and Drug Administration; 2020. 
6 Data on file, Study Report No. A131C-XC-17-528 and Report Amendment 01, Zoetis Inc. 
7 Animalytix Ruminant Segments MAT, ending May 2021.

For Further information please contact: 
Kathleen McGinty
Zoetis 
973-443-2169 
Kathleen.McGinty@zoetis.com

Dorothy Tate 
Bader Rutter 
309-333-8054 
dtate@bader-rutter.com   

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. 
© 2021 Zoetis Services LLC. All rights reserved. DKP-000020

CONTACT US

1-888-963-8471

Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2021 Zoetis Services LLC. All rights reserved.